Prolight Diagnostics AB (publ)

NGM:PRLD Stock Report

Market Cap: kr89.0m

Prolight Diagnostics Past Earnings Performance

Past criteria checks 0/6

Prolight DiagnosticsDie Erträge des Sektors -147.6% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Medical Equipment growing auf 6.5% pro Jahr stiegen. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 2431.7% pro Jahr gesunken.

Key information

-38.0%

Earnings growth rate

-11.6%

EPS growth rate

Medical Equipment Industry Growth6.2%
Revenue growth rate76.1%
Return on equity-11.5%
Net Margin-148.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?

Jul 14
Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?

Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In Growth

Nov 07
Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In Growth

We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business Growth

Jul 06
We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business Growth

Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In Growth

Mar 09
Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In Growth

Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth Plans

Nov 24
Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown
Beta

How Prolight Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:PRLD Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2319-28460
30 Sep 2332-22530
30 Jun 2333-17500
31 Mar 2336-16520
31 Dec 2236-12480
30 Sep 2215-17330
30 Jun 229-14230
31 Mar 223-9120
31 Dec 210-770
30 Sep 210-770
30 Jun 211-660
31 Mar 211-450
31 Dec 201-450
30 Sep 201-440
30 Jun 200-340
31 Mar 200-540
31 Dec 190-440
30 Sep 190-540
30 Jun 190-650
31 Mar 190-650
31 Dec 180-650
30 Sep 181-550
30 Jun 180-440
31 Mar 180-330
31 Dec 170-330
30 Sep 170-440
30 Jun 170-330
31 Mar 170-330
31 Dec 160-220
31 Dec 150-220

Qualität der Erträge: PRLD ist derzeit unrentabel.

Wachsende Gewinnspanne: PRLD ist derzeit unrentabel.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Ergebnisentwicklung: PRLD ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 43.9% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von PRLD verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: PRLD ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (-10.8%) erschwert.


Return on Equity

Hohe Eigenkapitalrendite: PRLD hat eine negative Eigenkapitalrendite (-8.66%), da es derzeit unrentabel ist.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.